Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Celltrion Launches Omlyclo in U.S., Targeting Early Lead in Omalizumab Biosimilar Market

Celltrion has entered the U.S. market for omalizumab biosimilars with the launch of Omlyclo, aiming to replicate the early market penetration it achieved in Europe and establish the product as a key…

  • Celltrion launches Omlyclo, first omalizumab biosimilar in U.S.
  • Introduced on October 5, offering 15% lower cost than reference product
  • Recognized as preferred drug by major PBMs, securing U.S. formulary placement

More from Tuesday 6 October →